Gary Patou - Dec 13, 2023 Form 4/A - Amendment Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
Director
Signature
/s/ Sherry Aulin, Attorney-in-fact
Stock symbol
XENE
Transactions as of
Dec 13, 2023
Transactions value $
-$311,898
Form type
4/A - Amendment
Date filed
12/15/2023, 09:50 PM
Date Of Original Report
Dec 15, 2023
Previous filing
Jun 2, 2023
Next filing
Jun 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XENE Common Shares Sale -$312K -7.6K -60.78% $41.05 4.9K Dec 14, 2023 See Note F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period.
F2 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.06, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3 By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou.

Remarks:

This amendment corrects the transaction date that was inaccurately reported on the original Form 4 due to a clerical error.